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The age-associated deterioration in cellular and
organismal functions associates with dysregulation
of nutrient-sensing pathways and disabled auto-
phagy. The reactivation of autophagic flux may
prevent or ameliorate age-related metabolic dys-
functions. Non-toxic compounds endowed with the
capacity to reduce the overall levels of protein acet-
ylation and to induce autophagy have been catego-
rized as caloric restriction mimetics (CRMs). Here,
we show that aspirin or its active metabolite salicy-
late induce autophagy by virtue of their capacity to
inhibit the acetyltransferase activity of EP300. While
salicylate readily stimulates autophagic flux in con-
trol cells, it fails to further increase autophagy levels
in EP300-deficient cells, as well as in cells in which
endogenous EP300 has been replaced by salicy-
late-resistant EP300 mutants. Accordingly, the pro-Cell Rep
This is an open access article under the CC BY-Nautophagic activity of aspirin and salicylate on the
nematode Caenorhabditis elegans is lost when the
expression of the EP300 ortholog cpb-1 is reduced.
Altogether, these findings identify aspirin as an
evolutionary conserved CRM.
INTRODUCTION
Macroautophagy (hereafter referred to as autophagy) acts as a
homeostatic pathway at both the cellular and organismal levels
(Mizushima and Komatsu, 2011). The finely tuned execution of
this multistep process (ensured by the coordinated activity of
specifically committed Atg proteins) eventually culminates in
the formation of a double-membrane organelle, the autophago-
some, in which bulk portions of the cytoplasm or specific organ-
elles are engulfed prior to their lysosomal hydrolase-mediated
degradation (He and Klionsky, 2009). Autophagy may be consid-
ered as one of the major anti-aging mechanisms because it
assures recycling (and hence rejuvenation) of damaged
cytoplasmic components, including entire organelles such asorts 22, 2395–2407, February 27, 2018 ª 2018 The Author(s). 2395
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
mitochondria (Pan et al., 2013; Rubinsztein et al., 2011; Sun
et al., 2016). Manipulations aiming at restoring or inducing auto-
phagy can reduce the incidence of age-related disease and
extend health span and lifespan (Lo´pez-Otı´n et al., 2016). The na-
ture of these interventions can be nutritional (i.e., fasting or
caloric restriction) (Heilbronn and Ravussin, 2003; Longo and
Mattson, 2014), behavioral (i.e., physical activity) (He et al.,
2012), or pharmacological. Thus,mTORC1 inhibition by rapalogs
(Lamming et al., 2013), activation of sirtuin-1 (SIRT1) with resver-
atrol (Wood et al., 2004), and supplementation of the natural
polyamine spermidine (Eisenberg et al., 2009) extend lifespan
in various model organisms in an autophagy-dependent manner
(Lo´pez-Otı´n et al., 2016). Importantly, overexpression of the
autophagy essential gene Atg5 is sufficient to expand lifespan
in mice (Pyo et al., 2013), indicating that autophagy is not only
necessary but even sufficient to enhance longevity.
Culture of cells in nutrient-free conditions, as well as fasting
regimens, leads to a reduction in the global levels of protein acet-
ylation (Eisenberg et al., 2014; Marin˜o et al., 2014). Reduced
acetylation may be explained by the diminution in the activity
of nuclear and cytoplasmic lysine-acetyltransferases (KAT)
secondary to a decrease in the nucleocytosolic levels of acetyl
coenzyme A (CoA), which is the sole donor of acetyl groups (Pie-
trocola et al., 2015a). As a consequence, blockade of acetyl CoA
biosynthesis has the same functional consequence as inhibition
of acetyltransferases or activation of the deacetylase activity of
sirtuins (Madeo et al., 2014) insofar that it triggers autophagy
(Marin˜o et al., 2014). Chemically unrelated agents, including ana-
cardic acid, hydroxycitrate, resveratrol, and spermidine (Pietro-
cola et al., 2015b), share the capacity to reduce protein acetyla-
tion and have been classified as caloric restriction mimetics
(CRMs). CRMs such as spermidine have widespread anti-aging
effects (Eisenberg et al., 2016; Pietrocola et al., 2016).
One of the major acetyltransferases that senses cytosolic
acetyl CoA levels is adenovirus early region 1A (E1A)-binding
protein p300, EP300, which also acts as a master repressor of
autophagy (Madeo et al., 2014). Of note, the autophagy inducer
spermidine competes with acetyl CoA for binding to the catalytic
site of EP300 and, therefore, limits its activity (Morselli et al.,
2011; Pietrocola et al., 2015b). Recently, aspirin has been shown
to inhibit the enzymatic activity of EP300 as well (Shirakawa
et al., 2016). Aspirin (acetylsalicylate), the pro drug of salicylate
(which is rapidly formed in vivo through the action of blood and
tissue acetylsalicylate hydrolases) (Ali and Kaur, 1983), is prob-
ably the pharmacological agent that has the most pleiotropic ef-
fects on human health, as it has broad anti-arteriosclerotic and
cancer-preventive effects (Baron et al., 2003; Ogawa et al.,
2008; Sandler et al., 2003). Beyond its inhibitory action on cyclo-
oxygenases, resulting in the inhibition of prostaglandin synthe-
sis, aspirin affects multiple signal transduction pathways.
For example, aspirin reportedly inhibits the activation of the
pro-inflammatory transcription factor nuclear factor kappa
light-chain enhancer of activated B cell (NF-kB) (Kopp and
Ghosh, 1994), and it directly activates the nutrient sensor protein
kinase AMP activated (PRKAA1), better known as AMPK (Haw-
ley et al., 2012).
Here we addressed the question as to whether aspirin might
have a broad autophagy-inducing effect and whether this effect2396 Cell Reports 22, 2395–2407, February 27, 2018might be explained by EP300 inhibition. We demonstrate that
aspirin fails to modulate autophagic flux in cells lacking EP300
or cells in which EP300 has been engineered to avoid aspirin
binding to the acetyl CoA-binding pocket of the enzyme. As a
confirmation of the evolutionarily conserved nature of this pro-
cess, we demonstrate that aspirin failed to further induce auto-
phagy in Caenorhabditis elegans strains deficient for the EP300
homolog CBP-1 or the essential autophagy gene products
ATG7 and BEC-1.
RESULTS
Salicylate Inhibits the Acetyltransferase Activity of
EP300
Anacardic acid (AA, also known as 6-pentadecylsalicylic acid)
represents the prototypical inhibitor of acetyltransferases from
the EP300/PCAF family. In a competitive interaction, the salicy-
late group of AA displaces the pyrophosphate group of CoA from
the KAT domain of EP300 (Ghizzoni et al., 2010).We investigated
the possibility that the active aspirin metabolite salicylate itself
would inhibit EP300 acetyltransferase activity via a similar mech-
anism as AA. In a cell-free-based assay, salicylate inhibited the
enzymatic activity of recombinant EP300 protein, resulting in
reduced acetylation of its natural substrate histone H3 on lysine
56 (H3K56) (Figures 1A and 1B). Importantly, the inhibition of
EP300 activity by salicylate was comparable to that of AA or
the synthetic EP300 inhibitor C646 (Figures 1A and 1B). This
inhibitory effect was achieved at a physiological concentration
of acetyl CoA (AcCoA), but it was attenuated by high-dose
AcCoA, in line with the idea that it occurred through a competi-
tive mechanism (Figures 1A and 1B), as recently proposed (Shir-
akawa et al., 2016). Consistently, the administration of salicylate
to two different cultured cell lines inhibited the EP300-mediated
acetylation of histone 2A (H2AK5) (Figures 1C and 1E) and
H3K56 (Figures 1D and 1F) in a dose-dependent manner. Alto-
gether, these data support the hypothesis that salicylate acts
as a direct competitive inhibitor of EP300.
Salicylate-Induced Autophagy Depends on EP300
Inhibition
Owing to its ability to directly acetylate key autophagic machin-
ery components, such as Atg5, Atg7, LC3 (Lee and Finkel, 2009),
and BECN1 (Sun et al., 2015), EP300 can transduce AcCoA
availability into autophagy inhibition. Based on these findings,
we determined whether salicylate would induce autophagy
through an EP300-dependent mechanism. U2OS cells stably
transfected with a fusion protein of GFP and microtubule-
associated proteins 1A/1B light chain 3B (GFP-LC3) manifested
the formation of cytoplasmic GFP-LC3 puncta upon treatment
with salicylate (Figure 2A). Importantly, the increase in number
of GFP-LC3 dots was even more prominent when auto-
phagosome-lysosome fusion was impaired by treatment with
bafilomycin A1 (BafA1), indicating that salicylate induced auto-
phagic flux (Figure 2A; Table S1). Consistently, human colorectal
cancer HCT116 cells treated with two different doses of sodium
salicylate exhibited enhanced lipidation of LC3 (as indicated by
an increase in its electrophoretic mobility), both in the presence
and in the absence of a lysosomal inhibitor (Figure 2B; Table S1).
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Figure 1. Salicylate Inhibits EP300 Acetyltransferase by Competing with AcCoA
(A and B) Direct inhibition of EP300 acetyltransferase activity by salicylate. Recombinant EP300 protein was incubated with its substrate histone H3 in the
presence of AcCoA, salicylate (5 mM), anacardic acid (AA, 50 mM), or C646 (10 mM), followed by immunoblotting to detect H3 acetylation on lysine 56
(A) and quantification (B) of 4 independent experiments (means ± SEM; *p < 0.05 and ***p < 0.001, one-way ANOVA compared to 10 mM AcCoA control group;
###p < 0.001, one-way ANOVA compared to 100 mM AcCoA; FC, fold change).
(C and D) Salicylate inhibits EP300 activity toward its natural substrates. Human colorectal cancer HCT116 (C) and human osteosarcoma U2OS cells (D) were
incubated for 16 hr with the indicated concentration of sodium salicylate and subjected to immunoblotting to evaluate H2A acetylation on lysine 5 (C) and H3
acetylation on lysine 56 (D) (quantified in E and F). Nutrient-free (NF) medium was used as a negative control of acetylation. Representative images of one
experiment are shown.
(E and F) Quantification of data depicted in (C) and (D) (means ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA compared to control
group).In line with the observation that salicylate bona fide promotes au-
tophagic flux, the addition of this compound to cell cultures
caused a diminution in the global levels of sequestosome-1
(SQSTM1/p62) (Figure 2B; Table S1) (Klionsky et al., 2016).
In addition, salicylate promoted the autophagy-dependent
degradation of long-lived protein, as detected by assessing pro-
tein turnover in cells in which proteins were labeled radioactively
with [14C]-valine (Bauvy et al., 2009; Dupont et al., 2017) (Fig-
ure 2C). Very similar results were obtained when protein turnover
was measured after pulse-labeling cells by means of the amino
acid analog L-azidohomoalanine (L-AHA), yielding azido-modi-
fied proteins that could be visualized by chemoselective ligation
with a fluorescent alkyne probe (Wang et al., 2017) (Figure 2D).
Importantly, the enhanced protein turnover elicited by salicylate
treatment was reversed by the simultaneous addition of
the autophagy inhibitor 3-methyladenine to the cell cultures
(3-MA), further strengthening the notion that salicylate stimulates
autophagic flux (Figures 2C and 2D). Salicylate uptake by cells is
mediated by sodium monocarboxylate transporters (Ganapathyet al., 2008), and cell line-dependent differences in the expres-
sion of these carriers may be at the origin of the relatively delayed
action of this compound on autophagy and EP300 inhibition. We
hence assessed autophagy induction upon short-term treatment
with growing concentrations of the cell-permeable salicylate
ester ethyl-salicylate. This agent rapidly induced autophagic
flux as it inhibited EP300 acetyltransferase activity (Figures
S1A–S1C; Table S1).
Incubation of cells with salicylate inhibited the activity of
mTORC1 complex (as monitored by the decreased phosphory-
lation of mTORC1 substrate ribosomal protein S6 kinase
beta-1 RPS6KB1, also known as p70S6K) and stimulated PRKAA
function (as indicated by its increased phosphorylation on Thr
172 by upstream kinases) (Figure S1D; Table S1). This event
might be sufficient for triggering autophagy, because PRKAA
can directly phosphorylate at least two pro-autophagic proteins,
namely, the unc-51-like autophagy-activating kinase 1 (ULK1)
(Egan et al., 2011; Kim et al., 2011) and BECN1 (Kim and
Guan, 2013). However, the pro-autophagic effect of salicylateCell Reports 22, 2395–2407, February 27, 2018 2397
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Figure 2. Aspirin Stimulates Autophagic Flux in Cultured Cells
(A and B) In vitro effects of the aspirin metabolite salicylate.
(A) U2OS cells expressing GFP-LC3 were treated with salicylate (5 mM), anacardic acid (AA, 50 mM), or C646 (10 mM) in the presence or absence of the lysosomal
inhibitor bafilomycin A1 (Baf A1), followed by quantitation of GFP-LC3-positive puncta. Representative images (left panel) and quantitation (right panel) of the
number of GFP-LC3 puncta per cell are depicted (**p < 0.01 and ***p < 0.001, unpaired t test compared with respective control condition). Data represent
means ± SD from one representative experiment (n = 3).
(B) HCT116 cells were incubated for 16 hr in the presence of growing concentrations of salicylate. Representative immunoblots of 4 independent experiments
show the LC3I-to-LC3II conversion (in the presence or absence of BafA1) and depletion of SQSTM1/p62.
(C and D) Analysis of autophagy-dependent long-lived protein (LLP) degradation upon treatment with salicylate.
(C) 3-methyladenine (3-MA)-sensitive degradation of [14C]-valine-labeled long-lived proteins was determined in HCT116 cells upon treatment with salicylate.
Values indicate means ± SD from one representative experiment (n = 3; **p < 0.01, unpaired t test compared to control condition).
(D) Autophagy-mediated degradation of L-azidohomoalanine (L-AHA)-labeled proteins was assessed in U2OS cells after treatment with salicylate or Rapamycin
(Rapa) in the presence or absence of 3-methyladenine. Maximum fluorescence intensity (MFI) values represent means ± SD from one representative experiment
(n = 3; *p < 0.05, unpaired t test compared to Co group).was still observable when the expression of PRKAA a1 subunit
was attenuated by transfection of specific small interfering
RNAs (siRNAs) (Figures S1E and S1F; Table S1). In accord
with previous findings (Din et al., 2012), salicylate still could
induce autophagy in mouse embryonic fibroblasts (MEFs) lack-
ing both the a1 and a2 PRKAA subunits (genotype PRKAAa1/
PRKAAa2/) (Figure S1G; Table S1).
Next, we investigated whether modulation of EP300 activity
would be responsible for the pro-autophagic activity of this com-
pound. Epistatic analyses indicated that salicylate was unable to
further increase autophagic flux in conditions of EP300 knockout
(Figures 3A and 3B; Figure S2A; Table S1) or knockdown
(Figure S2B; Table S1), suggesting that it stimulates autophagy
throughEP300 inhibition. In contrast, rapamycinwasable to stim-
ulate autophagy in conditions of EP300 depletion (Figure S2C).2398 Cell Reports 22, 2395–2407, February 27, 2018Interestingly, EP300-knockout cells failed to exhibit differences
in PRKAA activation levels or upon salicylate treatment when
compared to their wild-type (WT) counterparts, suggesting that
these pathways act independently of each other (Figure S2D).
Molecular modeling using the bi-substrate inhibitor Lys-CoA
(Bowers et al., 2010) docking site of EP300 (Figure 3C) sug-
gested that the introduction of two point mutations would be
compatible with AcCoA binding yet prevent salicylate to access
the catalytic site (Figure 3D). The knockout (KO)-EP300 HCT116
cells transfected with WT EP300 responded to salicylate by
increasing LC3 lipidation (Figure 3E) or generation of LC3 puncta
(Figure 3F). In contrast, replacement of endogenous EP300 by
the EP300 Y1414A/W1466K double mutant (DM) was unable
to restore autophagy induction by salicylate, whereas single
W1466K mutation partially impaired autophagic flux (Figures
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3E and 3F). In line with the prediction of the molecular model, the
double-mutated form of EP300 was still able to acetylate its
specific substrates (and hence to transfer the acetyl moiety of
AcCoA on protein), contrasting with its inability to functionally
interact with salicylate (Figure S2E).
As a master repressor of the autophagic pathway, EP300
mediates the acetylation of several components of autophagic
machinery, including that of LC3 (Huang et al., 2015; Sebti
et al., 2014). Indeed, LC3was deacetylated upon salicylate treat-
ment (Figure 3G), further suggesting that salicylate-induced
autophagy occurred through EP300 inhibition.
Injection of aspirin intomice induced signs of autophagy in vivo
in various organs, including heart (Figure 4A; Figures S3A–S3F)
and liver (Figure 4B; Figures S4A–S4F), as suggested by LC3 lip-
idation, SQSTM1/p62 degradation, and reduction in RPS6KB1
phosphorylation (statistically significant in the heart and with a
trend in the liver). These changes were detectable as early as
1 hr post-injection of salicylate, and they were paralleled by a
transient inhibition of EP300 activity, as indicated by the reduced
acetylation of its natural substrate H3K56 (Figures 4A and 4B).
However, the phosphorylation of PRKAA and that of its substrate
ACACA occurred at later time points (starting at 6 hr), suggesting
that PRKAA activation is unlikely to be involved in the early phase
of autophagy induction by aspirin. However, these results do not
exclude that PRKAA intervenes in later aspirin effects, which
involve complex physiological changes, including non-cell-
autonomous signals (Heintz et al., 2017). Importantly, the pro-
autophagic effect of salicylate was observed even when the
degradation of lysosomal content was inhibited by the injection
of leupeptin 2 hr before sacrifice, thus corroborating the evi-
dence that aspirin stimulates autophagic flux in the heart (Fig-
ure 4C; Figure S3G) and in the liver (Figure 4D; Figure S4G).
Next we assessed the effect of protracted oral administration
of aspirin (2 weeks) on cardiac autophagy in transgenic mice
overexpressing the tandem construct GFP-RFP-LC3 in cardio-
myocytes (Eisenberg et al., 2016; Hariharan et al., 2011). Aspirin
treatment resulted in an increase in the number of red/green
fluorescent (autophagosomes) and red fluorescent puncta
(autolysosomes), suggestive of autophagy induction in the heartFigure 3. EP300 Inhibition Is Epistatic to Salicylate-Induced Autophagy
(A and B) Administration of increasing doses of salicylate to human HCT116 colo
(WT), yet it fails to further stimulate autophagy in EP300 knockout (KO-EP300)
presence of bafilomycin A1) and quantitation of the number of GFP-LC3 puncta (
(*p < 0.05, unpaired t test compared with respective control conditions; **p < 0.
unpaired t test compared with respective control conditions; ###p < 0.001, unpai
(C and D) Computational docking model of the interactions between the CoA-bin
suggested to be important for the interaction with salicylate, but not for that with A
Experimental Procedures.
(E and F) HCT116 KO-EP300 cells, untagged (E) or stably expressing GFP-LC3 (F
double-mutated (DM) forms of EP300. In EP300-KO HCT116 cells transfected wit
completely abrogated, respectively, asmeasured by following the LC3I-to-LC3II c
(in the presence or absence of BafA1) (F). Representative immunoblots (E) and
puncta/cell (F) are depicted. Rapamycin (R) was used as a positive control of auto
*p < 0.05, **p < 0.01, and ***p < 0.001, unpaired t test compared with respective
(G) Salicylate reduces the EP300-dependent acetylation of autophagic protein LC
indicated concentration of salicylate followed by GFP-Trap-based immunoprecip
ylation status of GFP-LC3 immunoprecipitate was assessed bymeans of an antibo
panel). Values represent means ±SEM from three independent experiments (norm
ANOVA).
2400 Cell Reports 22, 2395–2407, February 27, 2018(Figure 4E). This aspirin-triggered increase in LC3 puncta also
occurred in mice treated with chloroquine, further supporting
the idea that aspirin indeed stimulated autophagic flux in vivo
(Figure 4E). Aspirin also potently stimulated one particular type
of organelle-specific autophagy, mitophagy (Shirakabe et al.,
2016b), in the heart, as monitored by means of a transgene-
encoded biosensor, mito-Keima (mt-Keima) (Katayama et al.,
2011; Shirakabe et al., 2016a), a mitochondrion-targeted protein
that undergoes a pH-dependent excitation shift when it localizes
in the acidic lysosomal compartment (Figure 4F).
Aspirin induced LC3 lipidation and SQSTM1 degradation in
most organs that we investigated and in particular in heart (Fig-
ure 4A), liver (Figure 4B), muscle (Figure S5A), and colon (Fig-
ure S5E), but not in brain (Figure S5I) and kidney (Figure S6D).
It is known that, when orally administered to healthy human
volunteers (Cerletti et al., 1984) or rodents (Higgs et al., 1987),
aspirin is rapidly converted into its active metabolites, in partic-
ular salicylate, which peaks around 20–30 min in the plasma.
However, aspirin metabolism has not been extensively studied
by modern metabolomics methods. At 1 hr after intraperitoneal
administration of aspirin, significant changes in the metabolome
of several organs, including heart (Figure 5A; Table S2), liver (Fig-
ure 5D; Table S2), skeletal muscle (Figure S5B; Table S2), colon
(Figure S5F; Table S2), brain (Figure S5J; Table S2), plasma (Fig-
ure S6A; Table S2), and kidney (Figure S6E; Table S2) occurred,
as monitored by mass spectrometry. More importantly, we as-
sessed the presence of peaks indicating the formation of aspirin
metabolites in these organs after administering either unlabeled
aspirin or [13C]-labeled aspirin, while searching for molecular en-
tities that differ in their mass by exactly 1 Da (Figures 5B and 5E;
Figures S5C, S5G, S5K, S6B, and S6F). Several among these un-
identified molecular entities were at least as abundant as salicy-
late (Figures 5C and 5F; Figures S5D, S5H, S5L, S6C, and S6G),
andmost of themwere organ specific (Figure 5G). Salicylate was
one among 13 aspirin metabolites that were clearly detectable in
all investigated organs (Figure 5H; Table S2). In line with our
in vitro observations and with the evidence that, in patients
taking up to 3 g aspirin/day, salicylate reaches 1–3 mM concen-
tration in plasma (Shirakawa et al., 2016), a dose range in whichrectal cancer cells stably expressing GFP-LC3 induces autophagy in wild-type
cells. Representative images (A, from Co versus 5-mM salicylate dose in the
B) are reported. Results (means ± SD) are from one representative experiment
01, unpaired t test compared with respective control conditions; ***p < 0.001,
red t test compared with WT control cells).
ding site of EP300 with Lys-CoA (C) or salicylate (D). Two amino acid residues
cCoA, weremutated (Y1414A andW1466K), as described in the corresponding
), were transfected with a vector carrying wild-type (WT), Y1414A, W1466K, or
h the W1466K or EP300 DM forms, salicylate-induced autophagy is partially or
onversion by immunoblotting (E) and the formation of GFP-LC3 positive puncta
automated videomicroscopy-based quantitation of the number of GFP-LC3
phagy induction (means ± SD). One representative experiment is shown (n = 3;
control group).
3. HCT116 cells stably expressing GFP-LC3 were incubated for 16 hr with the
itation. NF medium was used as a negative control of LC3 acetylation. Acet-
dy recognizing acetylated residues on proteins (left panel) and quantified (right
alized on immunoprecipitated GFP levels) (***p < 0.001 and **p < 0.01, one-way
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this molecule exhibits EP300 inhibitory and pro-autophagic
properties, salicylate thus likely represents one of the principal
metabolites responsible for aspirin activity. At this stage, it is
not clear why some organs are refractory to aspirin-mediated
induction of autophagy.
Aspirin Induces Autophagy in C. elegans via EP300
Inhibition
Upon treatment with aspirin, autophagic puncta (visualized as a
fusion protein between the LC3 worm ortholog LGG-1 and GFP)
were significantly upregulated in nematode embryos (Figure 6A).
The aspirin-induced increase in LGG-1 puncta was accompa-
nied by the degradation of the autophagic substrate SQST-1
(Figure 6B), and this was still observed after the addition of
BafA1, as compared to BafA1-only-treated animals (Figure 6C),
yet lost upon silencing of the autophagy essential genes bec-1
and atg-7 in the intestine of adult animals (Figure 6D). Consistent
with data obtained in mammalian cells, RNAi-mediated silencing
of cbp-1 (the C. elegans ortholog of EP300) was sufficient to
stimulate autophagy (Figure 6E). Importantly, autophagy medi-
ated by cbp-1 silencing could not be further enhanced by aspirin
treatment, indicating that cbp-1 inhibition was epistatic to
aspirin-induced autophagy (Figure 6E). Salicylate was able to
trigger autophagy in nematodes to an extent comparable with
aspirin treatment (Figure 6F). In agreement with the notion that
aspirin specifically promotes mitophagy in cardiomyocytes, we
found that silencing of dct-1, a putative ortholog of the mamma-
lian NIX/BNIP3L and BNIP3 and a key mediator of longevity and
mitophagy in C. elegans (Palikaras et al., 2015), abolished
aspirin-induced autophagy (Figure 6G), suggesting that aspirin
engages in selective autophagic degradation of mitochondria
in nematodes. In support of this observation, we demonstrated
that aspirin treatment induced the selective autophagic
degradation of the mitochondrial targeted Rosella (mt-Rosella)
biosensor (Figure 6H).
DISCUSSION
Based on the results described in this paper, aspirinmay be clas-
sified as a CRM. Indeed, aspirin fulfills all the criteria of a CRMFigure 4. Induction of Autophagy by Acetylsalicylic Acid In Vivo
(A and B) Representative immunoblots (n = 3mice per condition, n = 3 experiment
SQSTM1/p62 in the heart (A) and in the liver (B) (1, 3, and 6 hr after intraperitoneal (i
transient decrease in H3K56 acetylation, precedes PRKAA activation (asmonitore
PRKAA-mediated ACACA phosphorylation on Ser79), and it is accompanied by a
ensure equal protein content. Quantification of (A) and (B) are shown in Figures S
(C and D) Representative immunoblots (n = 2 experiments, n = 3 mice per group)
inhibitor leupeptin (Leup) in the heart (C) and liver (D) 6 hr after aspirin treatment.
(E and F) Long-term aspirin treatment enhances autophagic flux in the heart and
(E) Transgenic mice expressing the tandem-fluorescent mRFP-GFP-LC3 (Tg-tf
autophagic flux was assessed by the injection of chloroquine (10 mg/kg) 4 hr
and mRFP-puncta are shown in the left panel. Arrows, autophagosomes; arrow
autophagosomes (yellow bars) and autolysosomes (red bars) per cell ± SD from
compared to respective control conditions).
(F) Evaluation of mitochondrial autophagy by transgenic Mito-Keima mice. 2
aspirin-treated group (n = 3 mice/group). Representative images of Mito-Keima g
image of red-to-green Mito-Keima (561/457 nm) indicating mitophagy are shown
representative experiment (***p < 0.001, unpaired t test compared to control gro
2402 Cell Reports 22, 2395–2407, February 27, 2018(Madeo et al., 2014) as it (1) reduces protein acetylation by virtue
of its ability to inhibit the acetyltransferase activity of EP300,
(2) stimulates autophagic flux, and (3) has no cytotoxic activity.
Caloric restriction-based strategies or periodic fasting have
a favorable impact on health and longevity, both in non-human
primates (Colman et al., 2009; Mattison et al., 2017) and in hu-
man studies (Longo and Mattson, 2014), although studies
carried out in different research centers yielded controversial re-
sults regarding CR-mediated improved survival outcomes in rhe-
sus monkeys (Mattison et al., 2012). CRMs have been efficiently
used to sensitize tumor cells to chemotherapy (Pietrocola et al.,
2016), to treat obesity and metabolic syndrome (Canto´ et al.,
2012), and to prolong health span and lifespan (Eisenberg
et al., 2016, 2017;Madeo et al., 2014). Aspirin is known to reduce
the occurrence and progression of several human cancer
types (Li et al., 2015; Rothwell et al., 2012), to reverse high-fat
diet-induced insulin resistance (Kim et al., 2001), and to prolong
lifespan in mice (Strong et al., 2008). At this point, it remains to
be determined to which extent EP300 inhibition and autophagy
activation may effectively contribute to these aspirin effects
that apparently transcend its well-established anti-inflammatory
effects. Pre-clinical evidence suggests that a brain-permeable
aspirin derivative can reduce tau-mediated neurodegeneration
in an EP300-dependent fashion (Min et al., 2015). However, the
role of autophagy has not been explored in this setting. Epide-
miological and experimental data indicate that a high nutritional
uptake of the EP300 inhibitor spermidine counteracts cardiac
aging, both in humans and rodents (Eisenberg et al., 2016,
2017). In addition, spermidine reduces arteriosclerosis (Michiels
et al., 2016) and colon carcinogenesis (Miao et al., 2016) in
mouse models. These spermidine effects hence show a notable
overlap with those of aspirin, in accord with the observation that
both compounds inhibit EP300.
EP300 is a protein that undergoes cytoplasmic-nuclear shut-
tling and that presumably has rather distinct functions in the
cytoplasm and in the nucleus. Indeed, in this latter compart-
ment, EP300 acts as co-factor of several major transcription
factors, including tumor protein p53 (TP53), cAMP response
element-binding protein (CREB), promyelocytic leukemia
(PML), and hypoxia-inducible factor 1 alpha subunit (HIF-1a)s) showing LC3I-to-LC3II conversion and depletion of the autophagic substrate
.p.) injection of 100mg/kg aspirin). Autophagy induction in vivo is paralleled by a
d by upstream kinase-dependent phosphorylation on Thr172 and an increase in
reduction in the mTORC1 substrate PRS6K1. GAPDH levels were monitored to
3A–S3F and S4A–S4F, respectively.
showing LC3I-to-LC3II conversion in the presence or absence of the protease
Quantifications are presented in Figures S3G and S4G, respectively.
stimulates mitophagy.
-LC3) were treated for 2 weeks with 25 mg/kg aspirin by oral gavage, and
prior to euthanasia. Representative images of fluorescent GFP-LC3 puncta
heads, autolysosomes. Values in the right panel represent mean number of
one representative experiment (***p < 0.001 and ##p < 0.01, one-way ANOVA
-month-old C57BL/6J mouse hearts were examined in the control versus
reen (457 nm), Mito-Keima red (561 nm), the merged image, and a ratiometric
(left panel) and quantified (right panel). Values represent means ± SD from one
up). Scale bar, 50 mm.
Figure 5. Metabolomics Analysis of Aspirin-Derived Metabolites
The 6-week old C57BL/6 mice were injected with unlabeled aspirin (Asp) or [13C]-labeled aspirin (13CAsp) (100 mg/kg, i.p.), followed by mass spectrometry.
(A and D) Volcano plots relative to metabolites detected in the heart (A) and in the liver (D) after unlabeled aspirin injection. Log2FC of Asp/Co-downregulated
(green) or -upregulated (blue) metabolites with p value < 0.05 is represented.
(B and E) Volcano plots relative to metabolites detected in the heart (B) and in the liver (E) after [13C]-labeled aspirin injection. Log2FC of 13CAsp/Asp-down-
regulated (green) or -upregulated (red) metabolites with p value < 0.05 is depicted.
(C and F) Comparison between 13CAsp/Asp (red) and Asp/Co (blue). Log2FC significantly changed (p value < 0.05) in the heart (C) and in the liver (F) is graphed.
The blue box highlights salicylate, which represents a commonly upregulated metabolite in all organs assessed.
(G and H) Heatmap (Log2FC) of 13CAsp/Aspmetabolites in different organs (G) is shown. [13C]-Aspirin administration allows the identification of bona fide aspirin-
derivedmetabolites, which are distributed in an organ-specific fashion. Common upregulatedmetabolites are highlightedwith a blue box. Magnification is shown
in (H). Pre-annotatedmetabolites are as follows: SA[*]@4.14, salicylic acid, positivemode; GenA[*]@4.07(-), gentisic/2-pyrocatechuic acid; SA[*]@5.00(-), salicylic
acid, negative mode; SuA[*]@4.57(-), salicyluric acid; and SaGlc[*]@3.76(-), salicylate glucuronide. Details are available in Table S2.(Chan and La Thangue, 2001). While the immediate auto-
phagy-inducing function of EP300 can be explained by its
cytoplasmic action (given that enucleated cells still manifest
autophagy induction upon EP300 inhibition) (Marin˜o et al.,2014), it is well possible that the long-term effects of aspirin
also involve transcriptional reprogramming (Voora et al.,
2016) that is influenced by EP300. Future work will have to
address these possibilities.Cell Reports 22, 2395–2407, February 27, 2018 2403
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Figure 6. Aspirin Activates Autophagy in C. elegans and Reduces Aging in an Autophagy Gene-Dependent Manner
(A) Representative confocal images (left panel) of GFP::LGG-1-expressing embryos treated with 1 mM aspirin compared to vehicle and quantification of
GFP::LGG-1 puncta per embryo (right panel). Scale bar, 10 mm. Data represent means ± SEM of at least 15 images obtained across 2 independent experiments
(***p < 0.001, unpaired t test compared to vehicle-treated nematodes).
(B) Aspirin administration promotes proficient autophagic flux, as monitored by the reduction in levels of SQST-1/p62 autophagic substrate in the pharyngeal
region of SQST-1::GFP transgenic animals at day 1 of adulthood. Representative images (left panel) and quantification (right panel) are shown. Scale bar, 20 mm.
Data represent means ± SEM of n = 52 worms per group, pooled from three independent experiments (**p < 0.01, unpaired t test).
(C) Aspirin stimulates autophagic flux. Representative confocal images (left panel) and quantification (right panel) of GFP::LGG-1 puncta in the hypodermal seam
cells of L3–L4 larvae treated or not from the L4 stage of the first generation with 1 mM aspirin in the absence or in the presence of bafilomycin A1 (100 mg/mL).
Scale bar, 10 mm. Data represent means ± SEM of n = 196–329 seam cells, pooled from two independent experiments (***p < 0.001, one-way ANOVA compared
to vehicle – BafA1 treatment; ###p < 0.001, one-way ANOVA compared to vehicle + BafA1 treatment).
(D) Administration of aspirin induces the autophagy-dependent increase of pnhx-2mCherry::LGG-1 puncta in the intestine of 2-day-old adults, which is lost upon
siRNA-mediated depletion of BEC-1 and ATG-7. Epifluorescence images are depicted in the left panel (magnification indicates mCherry::LGG-1 puncta as
detected in aspirin-treated worms) and quantified in the right panel. Scale bar, 100 mm. Data represent means ± SEM of n = 15–28 worms per group, pooled from
two independent experiments (***p < 0.001, one-way ANOVA compared to vehicle Co RNAi).
(E) CBP-1 depletion is epistatic to aspirin-induced autophagy. RNAi-driven elimination of cbp-1 in transgenic animals expressing the GFP::LGG-1 reporter leads
to an increase in the number of GFP::LGG-1 puncta, which are not further increased by aspirin administration. Representative confocal images (left panel) and
corresponding quantification (right panel) are shown. Scale bar, 10 mm. Data represent means ± SEM (##p < 0.005 and **p < 0.01, unpaired t test compared to
Co RNAi-vehicle condition).
(F) Salicylate induces autophagy in C. elegans. Representative confocal images (left panel) and corresponding quantification (right panel) of GFP::LGG-1 puncta
in transgenic embryos treated with vehicle or salicylate (1 mM). Vehicle bar is shared with experiments depicted in (A) as assays were conducted in parallel. Data
represent means ± SEM of at least 15 images obtained in 2 independent experiments (***p < 0.001, unpaired t test compared to vehicle-treated nematodes).
(G) Knockdown of dct-1, a putative ortholog to the mammalian NIX/BNIP3L and BNIP3, reduces the number of GFP::LGG-1-positive foci in the epidermis of
aspirin-treated young adult wild-type animals. Representative confocal images (left panel) and corresponding quantification (right panel) are depicted. Scale bar,
10 mm. Values represent means ± SEM (**p < 0.01, unpaired t test compared with Co RNAi vehicle; #p < 0.05, unpaired t test compared with Co RNAi aspirin).
Co RNAi vehicle and aspirin bars are shared with data depicted in (E), as assays were conducted in parallel.
(H) Mitophagy is induced in nematodes treated with aspirin. Transgenic animals expressing the mt-Rosella biosensor in the body wall muscle cells were treated
with 1 mM aspirin or vehicle control. Mitophagy induction is signified by the reduction of the ratio between pH-sensitive GFP to pH-insensitive DsRed. Data
represent means ± SEM of n = 22–33 worms per group, pooled from two independent experiments (***p < 0.001, unpaired t test).Untargeted metabolomics analysis revealed that aspirin-
derived metabolites are generated in a highly organ-specific
fashion, although some metabolites, including salicylate, were
found ubiquitously. Future studies are required to identify the2404 Cell Reports 22, 2395–2407, February 27, 2018molecular structure of all aspirin metabolites and to measure
their pharmacological effects. In particular, it will be interesting
to learn which aspirin metabolites have autophagy-stimulating
properties.
EXPERIMENTAL PROCEDURES
Mouse Strains and Housing
Mice were maintained in specific pathogen-free conditions in a temperature-
controlled environment with 12-hr light/dark cycles, and they received food
and water ad libitum (except as noted). Animal experiments were in compli-
ance with the EU Directive 63/2010 and protocols were approved (APAFIS
2314-2015101617187579v1) by the Ethical Committee of the Cordeliers
Research Center (CEEA Darwin 5, registered at the French Ministry of
Research). The 6- to 7-week-old male WT C57BL/6 mice were obtained
from Envigo France (Gannat, France). For cardiac mitophagy assessment,
transgenic mice with cardiac-specific expression of Mito-Keima were gener-
ated on a C57BL/6J background with the murine a-myosin heavy-chain pro-
moter (experiments were approved by the Rutgers-New Jersey Medical
School’s Institutional Animal Care and Use Committee). For the evaluation
of the autophagic flux, transgenic mice with cardiac-specific expression
of tf-LC3 (Tg-tf-LC3) were generated on an FVB background with the
murine a-myosin heavy-chain promoter, kindly provided by Dr. L. Robbins
(Children’s Hospital, Cincinnati, OH) (experiments were approved by the
Rutgers-New Jersey Medical School’s Institutional Animal Care and Use
Committee).
In Vitro Acetylation Assay
Recombinant GST-EP300 fusion protein, corresponding to the amino acids
1,066–1,707 (14-418, Millipore), was assessed for its acetyltransferase activity
on the EP300 natural substrates recombinant histone H3 protein (M2503S,
New England Biolabs). Briefly, 1 mg EP300 Histone acetyl transferase (HAT)
domain was incubated in the presence of an HAT assay buffer (250 mM
Tris-HCl [pH 8.0], 50% glycerol, 0.5 mM EDTA, and 5 mM dithiothreitol),
1 mg substrate protein, and two different concentrations of AcCoA (A2056,
Sigma-Aldrich) for 1 hr at 30C in the presence of AA, C646, and sodium
salicylate. The reaction was stopped by adding 43 SDS buffer and boiling
the samples. Acetylation of substrate proteins was measured by immunoblot-
ting using specific antibodies against H3K56.
AHA-Protein Labeling
L-azidohomoalanine (L-AHA) (C10102, Thermo Fisher Scientific) labeling to
measure autophagic protein degradation was performed as described
in Wang et al. (2017), except with an extension of chase time to 18 hr in adap-
tation to U2OS cells. After chase, U2OS cells were treated for 16 hr in the
presence of 5 mM sodium salicylate or nutrient-free medium. Chemoselective
ligation between an AHA azido moiety and a fluorescently tagged alkyne
probe was used to monitor fluoresence intensity per cell using an automated
microscope Image Xpress Micro XLS (Molecular Devices).
Quantification and Statistical Analysis
Unless otherwise specified, quantitative data are presented as mean ± SD and
significance was assessed by unpaired t test by means of Prism software.
Additional details are available in the corresponding figure legends and in
the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.02.024.
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